CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
靶向免疫检查点通路分子的 CAR-T 细胞
英文原题：CAR-T Cells Targeting Immune Checkpoint Pathway Players.
查看英文原题
CAR-T Cells Targeting Immune Checkpoint Pathway Players.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 细胞疗法已成为一种非常有前景的抗血液肿瘤免疫疗法。本报告聚焦于靶向肿瘤细胞表达的免疫检查点蛋白的CAR-T 细胞。CD70、CD47、CD80、CD86、B7H3、B7H4、PDL-1、TIGIT CAR-T 细胞及其他CAR-T 细胞被讨论为清除表达检查点蛋白的肿瘤细胞的有效方法。靶向检查点通路的CAR-T 细胞疗法是一种有前景的疗法，可减少抑制性信号通路。本综述强调了靶向免疫检查点通路的CAR-T 细胞的未来方向和前景。
展开英文摘要原文
CAR (Chimeric antigen receptor)-T cell therapy has become a very promising type of immunotherapy against hematological cancers. This report is focused on CAR-T cells targeting immune checkpoint proteins expressed on tumor cells.
The CD70, CD47, CD80, CD86, B7H3, B7H4, PDL-1, TIGIT CAR-T cells and other CAR-T cells are discussed as an effective approach to deplete tumor cells expressing checkpoint proteins. CAR-T cell therapy targeting checkpoint pathways is a promising therapy to decrease inhibitory signaling pathways. The review highlights future directions and perspectives in CAR-T cells targeting immune checkpoint pathways.
论文信息
- 作者
- Golubovskaya V
- 单位
- Promab Biotechnologies, Richmond, CA 94806, USA.Italy
- 文献类型
- 综述 · 非美国政府资助研究
- 期刊
- Frontiers in bioscience (Landmark edition)2022 Apr 2
- 原文标识
- PubMed 35468680 · DOI 10.31083/j.fbl2704121